Assessment and Significance of Left Ventricular Mass by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy

Olivotto, Iacopo; Maron, Martin S.; Autore, Camillo; Lesser, John R.; Rega, Luigi; Casolo, Giancarlo; Santis, Marcello De; Quarta, Giovanni; Nistri, Stefano; Cecchi, Fabiola; Salton, Carol J; Udelson, James E.; Manning, Warren J.; Maron, Barry J.

doi:10.1016/j.jacc.2008.04.047

Cited by 278 publications

(205 citation statements)

References 29 publications

Supporting

Mentioning

180

Contrasting

Unclassified

Order By: Relevance

“…Women with HCM are older at presentation, more symptomatic, and more likely to have resting LV obstruction compared with men 24. While LV mass indexed for body surface area is lower in women, suggesting milder phenotypic expression25 (Figure 1), women are more prone to heart failure–related mortality and HCM‐related complications 26, 27. Furthermore, women with HCM have comparable rates of SCD compared with men,24, 28, 29 although they may be less exposed to arrhythmic events triggered by strenuous exercise 30, 31.…”

Section: Demographic Featuresmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy

Finocchiaro

Magavern

Sinagra

et al. 2017

JAHA

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Demographic Featuresmentioning

confidence: 99%

Section: Demographic Featuresmentioning

confidence: 99%

Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy

Finocchiaro

Magavern

Sinagra

et al. 2017

JAHA

Self Cite

View full text Add to dashboard Cite

show abstract

“…13 An association between LGE and maximum LV wall thickness has also been reported. 25 LA dilatation, a surrogate marker of diastolic dysfunction, is also associated with LGE. 26 Mortality in our population, although low, was in all cases of cardiovascular cause (heart failure).…”

Section: Discussionmentioning

confidence: 99%

Phenotypic expression in hypertrophic cardiomyopathy and late gadolinium enhancement on cardiac magnetic resonance

Caetano

Botelho

Trigo

et al. 2014

Revista Portuguesa de Cardiologia (English Edition)

View full text Add to dashboard Cite

Introduction and Aim:The prognostic value of late gadolinium enhancement (LGE) for risk stratification of hypertrophic cardiomyopathy (HCM) patients is the subject of disagreement. We set out to examine the association between clinical and morphological variables, risk factors for sudden cardiac death and LGE in HCM patients. Methods: From a population of 78 patients with HCM, we studied 53 who underwent cardiac magnetic resonance. They were divided into two groups according to the presence or absence of LGE. Ventricular arrhythmias and morbidity and mortality during follow-up were analyzed. Results: Patients with LGE were younger at the time of diagnosis (p=0.046) and more often had a family history of sudden death (p=0.008) and known coronary artery disease (p=0.086). On echocardiography they had greater maximum wall thickness (p=0.007) and left atrial area (p=0.037) and volume (p=0.035), and more often presented a restrictive pattern of diastolic dysfunction (p=0.011) with a higher E/E ratio (p=0.003) and left ventricular systolic dysfunction (p=0.038). Cardiac magnetic resonance supported the association between LGE and previous echocardiographic findings: greater left atrial area (p=0.029) and maximum wall thickness (p<0.001) and lower left ventricular ejection fraction (p=0.056). Patients with LGE more often had an implantable cardioverter-defibrillator (ICD) (p=0.015). At follow-up, no differences were found in the frequency of ventricular arrhythmias, appropriate ICD therapies or mortality. Conclusions:The presence of LGE emerges as a risk marker, associated with the classical predictors of sudden cardiac death in this population. However, larger studies are required to confirm its independent association with clinical events. PALAVRAS-CHAVE

show abstract

“…32) Cardiac magnetic resonance is a useful tool with which to assess LV mass and myocardial fibrosis in HCM. 33,34) Therefore, further investigations are warranted to elucidate the significance and mechanisms of adiponectin for LV hypertrophy and diastolic dysfunction in patients with HCM.…”

Section: Discussionmentioning

confidence: 99%

Plasma Adiponectin Levels and Left Ventricular Remodeling in Hypertrophic Cardiomyopathy

et al. 2010

View full text Add to dashboard Cite

SummaryAdiponectin, which is an adipose-derived protein with antiatherosclerogenic activities, has been reported to be elevated in patients with heart failure. However, there are no reports on the significance of adiponectin in patients with hypertrophic cardiomyopathy (HCM). The purpose of this study was to elucidate the clinical significance of plasma adiponectin levels in HCM patients.Clinical characteristics, echocardiographic parameters, and levels of plasma B-type natriuretic peptide (BNP) and adiponectin were evaluated in 106 HCM patients. The plasma adiponectin levels were 10.8 ± 6.3 (range, 2.7-37.3) μg/mL. Plasma adiponectin levels were positively related to age and inversely related to body mass index (BMI). Among echocardiographic parameters, % fractional shortening (r = -0.20, P = 0.03) and maximum LV wall thickness (r = -0.23, P = 0.02) were inversely related to plasma adiponectin levels. A significant correlation between plasma adiponectin levels and BNP levels was also observed (r = 0.27, P = 0.005). In multivariate analysis, BMI, % fractional shortening, and plasma BNP levels were independent predictors of plasma adiponectin levels.Plasma adiponectin levels are associated with impaired LV systolic function in HCM patients, but not with the LV outflow gradient. Together with BNP, adiponectin can be a useful biomarker for assessing disease severity in HCM patients. (Int Heart J 2010; 51: 51-55) Key words: Hypertrophic cardiomyopathy, Adiponectin, B-type natriuretic peptide, LV remodeling, Heart failure H ypertrophic cardiomyopathy (HCM), a relatively prevalent genetic cardiac disease caused by mutations in genes encoding sarcomere proteins, is clinically defined as left ventricular (LV) hypertrophy with heterogeneous clinical and morphological features in the absence of other cardiovascular diseases.1,2) The clinical and morphological features are diverse and the natural history varies from an asymptomatic and benign clinical course to sudden premature death. [3][4][5] Biomarkers are molecules that are objectively measured by laboratory techniques, which can give us useful information in patients with cardiovascular disease, including HCM. 6) Adipocytokine adiponectin is an adipose-derived protein and shows antiatherosclerogenic and insulin-sensitizing effects. The low plasma levels of adiponectin are associated with type 2 diabetes and ischemic heart disease. [7][8][9][10][11] Moreover, the novel cardiovascular effects of adiponectin have attracted considerable attention in patients with LV hypertrophy and chronic heart failure.12-16) However, the significance of adiponectin has not yet been evaluated in patients with HCM. The purpose of this study was to elucidate the significance of plasma adiponectin levels in HCM. MethodsPatients and study protocol: The study group included 106 patients with HCM diagnosed based on echocardiographic demonstration of a hypertrophied left ventricle (maximum wall thickness ≥ 15 mm) in the absence of systemic hypertension or other cardiac disease that could produc...

show abstract

Assessment and Significance of Left Ventricular Mass by Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy

Cited by 278 publications

References 29 publications

Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy

Impact of Demographic Features, Lifestyle, and Comorbidities on the Clinical Expression of Hypertrophic Cardiomyopathy

Phenotypic expression in hypertrophic cardiomyopathy and late gadolinium enhancement on cardiac magnetic resonance

Plasma Adiponectin Levels and Left Ventricular Remodeling in Hypertrophic Cardiomyopathy

Contact Info

Product

Resources

About